This study is looking at whether Semaglutide, a medication given by injection once a week, can affect tobacco use and related behaviors in adults who smoke daily and have obesity (BMI of 30 or higher). You would receive either Semaglutide or a placebo (inactive substance) for 12 weeks. Researchers will measure changes in cigarette smoking after 12 weeks. This study is for people aged 18 to 65 who smoke more than 2 cigarettes a day, have obesity, and do not currently want to quit smoking. The study aims to enroll 40 participants, but its current recruitment status is unclear.

Study design

This is a pilot randomized trial, meaning participants are randomly assigned to receive either Semaglutide or a placebo. The study plans to enroll 40 participants.

What's involved

Participants will receive weekly injections for 12 weeks, with the dose gradually increasing. The study will also involve assessments of tobacco use and health factors.

Compensation

Not stated in the trial record.

Follow-up

The primary outcome, cigarette smoking, is measured at 12 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.